Login
Pfizer buys digital health company in ‘historic’ deal
Global law firm DLA Piper has advised a leading digital health company on its acquisition by Pfizer Australia Holdings Pty Limited (Pfizer Australia).
Emma Musgrave
Firms: DLA Piper (ResApp Health Limited); Undisclosed (Pfizer Australia)
To continue reading the rest of this article, please log in.
Create free account to get unlimited news articles and more!
Deal: Pfizer Australia has acquired ResApp Health Limited (ResApp) by a scheme of arrangement.
Value: $180 million
Area: Merger and acquisition
Key players: The DLA Piper cross-practice team was led by partners James Nicholls, Matt Spain, Greg Bodulovic and Fleur Gibbons, with assistance from Matthew Nowotny-Walsh, Nicole Breschkin, Kit Lloyd, Alex Wong, Margit Baranyay, Emily Donley, Ella Blythe, Madina Eira and Joshua Scoles.
Deal significance: ResApp is described as a leading digital health company that develops smartphone applications for the diagnosis and management of respiratory disease.
According to a statement provided by DLA Piper, ResApp’s machine-learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware.
Meanwhile, Pfizer Australia is a wholly owned subsidiary of Pfizer Inc, one of the world’s premier innovative global biopharmaceutical companies striving to apply science and its global resources to bring therapies to people that extend and significantly improve their lives.
“We were thrilled to advise ResApp on this historic deal for the company,” said DLA Piper partner James Nicholls.
“We look forward to seeing the continued development of the ResApp technology.
“The transaction highlighted the strength of DLA Piper’s interconnected Australian service offering. Our public M&A, litigation and regulation, competition and intellectual property teams worked seamlessly to deliver to client the desired result.”
